這是什麽意思？謝謝

There is a high chance that we will see at least the same outcome as we do starting with another inhibitor — such as Tarceva (erlotinib), Iressa (gefitinib) or Gilotrif (afatinib) — followed by Tagrisso if you develop the T790M mutation. If, in addition, we don’t have the side effect of a rash, then we have a clear winner. This is based on the numbers that we have. It looks very promising, but we have seen promising before and it isn’t always confirmed. We have to be cautious. We will be disappointed if Tagrisso does not become the first-line choice.

also

Tagrisso (osimertinib, AZD9291) 80mg once-daily tablet is the first medicine indicated for the treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive NSCLC. 

does it mean it also could be used without beingT790M positive?

所有跟帖： 

• 我的理解： -鍋沿- ♂ (563 bytes) () 06/14/2017 postreply 09:56:42

• 謝謝鍋兄弟，我的情況是 -hz82000- ♀ (167 bytes) () 06/14/2017 postreply 10:43:47

• 基因突變陰性的靶向藥取得好效果的也有20%機率 -puppylover- ♂ (140 bytes) () 06/14/2017 postreply 10:45:15

• 可是為什麽不用泰瑞沙呢？ -hz82000- ♀ (169 bytes) () 06/14/2017 postreply 10:54:59

• 我想我理解你的意思，如果Iressa出現耐藥，也就T790M發生了變化，也就是說EGFR 出現陰性，這4種藥 -鍋沿- ♂ (239 bytes) () 06/14/2017 postreply 13:04:26

• 再謝，我查查 -hz82000- ♀ (0 bytes) () 06/14/2017 postreply 14:08:50

• Tagrisso 主要用於EGFR T790M陽性病人其它靶向藥物產生耐藥後，的第二選擇，它也作用於EGFR 的亞群，既 -鍋沿- ♂ (200 bytes) () 06/14/2017 postreply 14:59:27

• 謝謝，我們是盲試，希望work -hz82000- ♀ (0 bytes) () 06/14/2017 postreply 15:11:48

• 而Gilotrif 作用於不同的4個表皮生長因子，Tagrisso 隻作用於1個表皮生長因子EGFR 及其亞群。這是我的理解 -鍋沿- ♂ (0 bytes) () 06/14/2017 postreply 15:19:58

• 這個我查了中國市場有，我問問醫生 -hz82000- ♀ (0 bytes) () 06/14/2017 postreply 15:51:47